[go: up one dir, main page]

AR061790A1 - Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento - Google Patents

Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento

Info

Publication number
AR061790A1
AR061790A1 ARP070102934A ARP070102934A AR061790A1 AR 061790 A1 AR061790 A1 AR 061790A1 AR P070102934 A ARP070102934 A AR P070102934A AR P070102934 A ARP070102934 A AR P070102934A AR 061790 A1 AR061790 A1 AR 061790A1
Authority
AR
Argentina
Prior art keywords
formulations
oral administration
immediate release
manufacture
pharmaceutical composition
Prior art date
Application number
ARP070102934A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR061790A1 publication Critical patent/AR061790A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica solida para administracion oral que comprende el compuesto de formula (1), o una de sus sales aceptables desde el punto de vista farmacéutico y por lo menos un desintegrante, donde la proporcion de compuesto 1 es menor de aproximadamente 10% del peso de la composicion. Se brindan formulaciones de liberacion inmediata para administracion oral de un antagonista del receptor de trombina. Ciertas formulaciones de carga de principio farmacéutico activo (PFA) superior demuestran captacion suficiente de humedad luego del almacenamiento en condiciones de estrés para retrasar la disolucion. Las formulaciones de la presente incorporan cargas de PFA inferiores o elevadas relaciones de desintegrante a PFA, que se encontro son necesarias para lograr las velocidades de desintegracion requeridas para un desempeno de liberacion inmediata. También se revela el uso de estas composiciones para la manufactura de un medicamento para el tratamiento de enfermedades coronarias.
ARP070102934A 2006-06-30 2007-06-29 Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento AR061790A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81782106P 2006-06-30 2006-06-30

Publications (1)

Publication Number Publication Date
AR061790A1 true AR061790A1 (es) 2008-09-24

Family

ID=38895141

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102934A AR061790A1 (es) 2006-06-30 2007-06-29 Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento

Country Status (18)

Country Link
US (2) US20080031943A1 (es)
EP (2) EP2034969B1 (es)
JP (2) JP5116764B2 (es)
KR (1) KR20090023670A (es)
CN (2) CN104922054A (es)
AR (1) AR061790A1 (es)
AU (1) AU2007269733B2 (es)
BR (1) BRPI0713935A2 (es)
CA (1) CA2656395C (es)
CL (1) CL2007001923A1 (es)
CO (1) CO6150126A2 (es)
ES (2) ES2616354T3 (es)
MX (1) MX2009000131A (es)
NO (1) NO20090467L (es)
PE (1) PE20080376A1 (es)
TW (1) TWI367112B (es)
WO (1) WO2008005353A2 (es)
ZA (1) ZA200900350B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
US8624050B2 (en) * 2007-06-22 2014-01-07 General Electric Company Solution process for transparent conductive oxide coatings
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
SI2438060T1 (sl) 2009-06-04 2014-04-30 Merck Sharp & Dohme Corp. Aktivni metabolit trombin receptorskega antagonista
MX2011013091A (es) 2009-06-08 2012-01-12 Schering Corp Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel.
CN102442965B (zh) * 2010-09-30 2013-12-11 天津药物研究院 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途
WO2017134200A1 (en) 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
MX2020008137A (es) * 2018-02-02 2020-10-19 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Formulaciones orales y usos de las mismas.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61137813A (ja) * 1984-12-07 1986-06-25 Sawai Seiyaku Kk 持続性セフラジン製剤
JPS63162620A (ja) * 1986-12-25 1988-07-06 Teisan Seiyaku Kk 遅溶性顆粒及びそれを用いた持続性複合顆粒
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
JPH10130142A (ja) * 1996-10-31 1998-05-19 Zensei Yakuhin Kogyo Kk 放出持続型圧縮製剤
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
KR100393492B1 (ko) * 1997-11-25 2003-08-02 쉐링 코포레이션 트롬빈 수용체 길항제
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
ES2291323T3 (es) 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
ATE282041T1 (de) * 2001-02-23 2004-11-15 Ortho Mcneil Pharm Inc Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
ATE538090T1 (de) 2001-04-19 2012-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 2-iminopyrrolidin- derivaten
MXPA04003610A (es) * 2001-10-18 2004-07-27 Schering Corp Analogos de himbacina como antagonistas del receptor de trombina.
JP4558331B2 (ja) * 2002-04-16 2010-10-06 シェーリング コーポレイション 三環式トロンビンレセプターアンタゴニスト
DE10317816A1 (de) 2003-04-16 2004-11-04 Claas Selbstfahrende Erntemaschinen Gmbh Feldhäcksler mit positionierbarer Fahrerkabine
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
CN101384259A (zh) * 2005-12-22 2009-03-11 先灵公司 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
EP2037909A2 (en) * 2006-06-30 2009-03-25 Schering Corporation Solid dose formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
MX2009010268A (es) * 2007-03-23 2009-11-09 Schering Corp Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.

Also Published As

Publication number Publication date
WO2008005353A2 (en) 2008-01-10
AU2007269733B2 (en) 2013-02-21
EP2034969A2 (en) 2009-03-18
CN101511345A (zh) 2009-08-19
PE20080376A1 (es) 2008-06-13
JP5116764B2 (ja) 2013-01-09
AU2007269733A1 (en) 2008-01-10
EP2491922B1 (en) 2017-01-04
US20080031943A1 (en) 2008-02-07
ES2616405T3 (es) 2017-06-13
TWI367112B (en) 2012-07-01
CO6150126A2 (es) 2010-04-20
ZA200900350B (en) 2010-01-27
CA2656395C (en) 2016-12-13
CA2656395A1 (en) 2008-01-10
CN104922054A (zh) 2015-09-23
TW200810792A (en) 2008-03-01
BRPI0713935A2 (pt) 2012-12-04
JP2012126752A (ja) 2012-07-05
MX2009000131A (es) 2009-01-26
JP2009542678A (ja) 2009-12-03
KR20090023670A (ko) 2009-03-05
US20170224666A9 (en) 2017-08-10
EP2491922A1 (en) 2012-08-29
EP2034969B1 (en) 2017-01-11
WO2008005353A3 (en) 2008-06-26
CL2007001923A1 (es) 2008-02-08
US20160193196A1 (en) 2016-07-07
NO20090467L (no) 2009-03-19
ES2616354T3 (es) 2017-06-12

Similar Documents

Publication Publication Date Title
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
UA116334C2 (uk) Тверді форми дозування бендамустину
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
AR041370A1 (es) Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
ES2435240T3 (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica
PE20061449A1 (es) Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion
SI3079671T1 (en) Oral disintegration solid dosage form containing an esterol component
AR062167A1 (es) Sistema de administracion gastrorretentivo
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
RU2008113439A (ru) Композиции с замедленным высвобождением лекарственного средства
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
ES2624231T3 (es) Coadyuvante de formación de comprimidos a base de lactosa y celulosa
MY157790A (en) Trazodone composition for once a day administration
CO5060477A1 (es) Forma de dosificacion de nefazodona
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
AU2014299447B2 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
ES2535106T3 (es) Composiciones farmacéuticas de rosuvastatina cálcica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal